Page last updated: 2024-11-07

s-nitrosocaptopril

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

S-nitrosocaptopril: manifests nitrovasodilatory activity, inhibits angiotensin converting enzyme activity & inhibits platelet aggregation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID129596
SCHEMBL ID3911398
MeSH IDM0166905

Synonyms (12)

Synonym
s-nitrosocaptopril
l-proline, 1-(2-methyl-3-(nitrosothio)-1-oxopropyl)-, (s)-
(2s)-1-[(2s)-2-methyl-3-nitrososulfanylpropanoyl]pyrrolidine-2-carboxylic acid
122130-63-6
SCHEMBL3911398
DTXSID20153527
J-004766
(s)-1-((s)-2-methyl-3-(nitrosothio)propanoyl)pyrrolidine-2-carboxylic acid
HNIULCDUASSKOM-RQJHMYQMSA-N
snocap
l-proline, 1-[(2s)-2-methyl-3-(nitrosothio)-1-oxopropyl]-
(2s)-1-[(2s)-2-methyl-3-(nitrososulfanyl)propanoyl]pyrrolidine-2-carboxylic acid

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Serum chemistry and hematology tests performed in the subacute toxicity studies revealed no adverse effects of oral CapNO except for a significant decrease in cholesterol levels in hypertensive SHR rat."( Acute and subacute toxicity and efficacy of S-nitrosylated captopril, an ACE inhibitor possessing nitric oxide activities.
Jia, L; Lin, M; Pei, R; Yang, X, 2001
)
0.31

Pharmacokinetics

ExcerptReferenceRelevance
" Simultaneous on-line analyses of pharmacodynamic and pharmacokinetic profiles of CapNO in catheterized awake rats of spontaneous hypertension (SHR) showed acute decreases in mean arterial pressure (MAP), concomitant with the corresponding increases in plasma levels of CapNO after po or iv administration."( Physicochemistry, pharmacokinetics, and pharmacodynamics of S-nitrosocaptopril crystals, a new nitric oxide donor.
Guo, W; Jia, L; Young, X, 1999
)
0.55
" The present studies were aimed at testing the hypothesis that S-nitrosylated captopril (CapNO), a novel crystalline nitric oxide (NO) donor, readily permeates both in vitro and in vivo endothelial monolayers, resulting in its pharmacodynamic effects."( In vitro and in vivo assessment of cellular permeability and pharmacodynamics of S-nitrosylated captopril, a nitric oxide donor.
Jia, L; Wong, H, 2001
)
0.31

Bioavailability

ExcerptReferenceRelevance
", t(1/2), T(max), C(max), V(d), AUC, and oral bioavailability were analyzed to understand the dose-dependent potency and effective period of CapNO."( Physicochemistry, pharmacokinetics, and pharmacodynamics of S-nitrosocaptopril crystals, a new nitric oxide donor.
Guo, W; Jia, L; Young, X, 1999
)
0.55

Dosage Studied

ExcerptRelevanceReference
" Captopril (10(-6) M) and SnoCap (10(-6) M) equally inhibited contraction to angiotensin I, inducing a 50-fold shift in the dose-response curve."( S-nitrosocaptopril. II. Effects on vascular reactivity.
Andon, N; Cooke, JP; Loscalzo, J, 1989
)
1.72
" S-nitrosocaptopril produced acute reductions in mean arterial pressure after both oral dosing (5, 10, 50 mg/kg) to chronically-catheterized awake rats and intravenous administrations (0."( The effects of S-nitrosocaptopril on renal filtration and blood pressure in rats.
Blantz, RC; Jia, L, 1998
)
1.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (34)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (5.88)18.7374
1990's11 (32.35)18.2507
2000's9 (26.47)29.6817
2010's10 (29.41)24.3611
2020's2 (5.88)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.57

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.57 (24.57)
Research Supply Index3.56 (2.92)
Research Growth Index5.13 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.57)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (2.94%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other33 (97.06%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]